comparemela.com

Page 2 - Coated Balloon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boston Scientific AGENT Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB

United statesRobertw yehJanarthanan sathananthanDrug administrationBoston scientific corporation onBoston scientificHarvard medical schoolCardiovascular research foundationBeth israel deaconess medical centerBoston scientific corporationCoated balloonTranscatheter cardiovascular therapeuticsCardiovascular researchKatz silver family professorHarvard medicalInterventional cardiology therapies

CRF Announces TCT 2023 Late-breaking Clinical Trials

Annual Scientific Symposium will take place October 23-26 in San Francisco

United statesSan franciscoFiras zahrTicagrelor monotherapyRobertl smithCardiovascular research foundationMoscone centerYear clinicalEchocardiographic outcomesRisk randomized trialYear outcomesRisk trialLeft atrial appendage occlusionTranscatheter aortic valve replacementHigh risk patientsSymptomatic severe native aortic regurgitation

BIOPACT RCT Subgroup Analyses Show Consistently Great Results for Passeo-18 Lux Drug-Coated Balloon

No statistical difference observed across sub-analyses for diabetes, lesion length, calcium, bailout stenting and occlusions in head-to-head study comparing Passeo-18 Lux DCB to In.Pact Admiral DCB

United statesFrance generalKoen delooseGroup of companiesLeipzig interventional coursePact admiralParis vascular insightsAccessed juneCoated balloon

Research Report On Drug Coated Balloon(DCB) Market

Research Report On Drug Coated Balloon(DCB) Market

South africaUnited statesB braun melsungenEurocor gmbParmeet singhAsia pacificConsulting privateKoninklijke philipsMarket researchGrandpharma china co ltdAcotec scientific holdingsResearch studyBoston scientificDhirtek business researchGlobal drug coated balloonMarket report

Concept Medical Inc : Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

TAMPA, Fla., May 1, 2023 /PRNewswire/ The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for

United statesCardiovascular research foundationConcept medical incInvestigational device exemptionMagictouch sirolimus coated balloonSmall vesselsCoated balloonSmall vesselConcept medicalSirolimus coated balloonIn stent restenosisVessel diseaseDrug coated balloonsDrug eluting stentsHybrid bifurcationMartin leon

vimarsana © 2020. All Rights Reserved.